1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
(
- Contribution to journal › Article
- 2021
-
Mark
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
(
- Contribution to journal › Article
- 2020
-
Mark
Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
(
- Contribution to journal › Article
- 2018
-
Mark
The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis : A review
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)
(
- Contribution to journal › Article
-
Mark
Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
(
- Contribution to journal › Article
- 2016
-
Mark
No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF
(
- Contribution to journal › Article
-
Mark
Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes
(
- Contribution to journal › Article
-
Mark
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios : better diagnostic markers of Alzheimer disease
(
- Contribution to journal › Article
- 2015
-
Mark
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
(
- Contribution to journal › Article